Giacomo Canesin, PhD

Principal Scientist at Vor Biopharma

Giacomo Canesin, PhD has a diverse work experience across various research institutions. Giacomo is currently serving as a Senior Scientist in Preclinical Science at Vor Biopharma, a role they have held since July 2022. Prior to this, they were a Scientist II in Cancer Immunotherapy at Vor Biopharma from June 2020 to July 2022.

Before joining Vor Biopharma, Giacomo worked as a Research Fellow at Beth Israel Deaconess Medical Center from September 2017 to May 2020. Giacomo served as a Postdoctoral Researcher at Lund University from March 2013 to August 2017. Prior to that, they were a PhD Fellow at Universidad Autonoma de Madrid - Instituto de Investigaciones Biomedicas "A. Sols" from September 2008 to December 2012.

Giacomo's experience also includes a Visiting PhD Fellow position at Weill Medical College of Cornell University from September 2011 to December 2011, a Visiting Fellow position at CNIO from September 2006 to March 2007, and an Exchange Student role at University of Ulster - School of Biomedical Sciences from September 2002 to June 2003.

Giacomo Canesin, PhD, completed their education in a chronological manner. Giacomo began their studies in 2000 at the University of Camerino, where they obtained a Bachelor's degree in Biology/Biological Sciences, General in 2004. Following this, from 2004 to 2006, they pursued a Master of Science - MS in Biomolecular Sciences at the same institution. Continuing their academic journey, from 2008 to 2012, Giacomo Canesin enrolled at the Universidad Autónoma de Madrid, where they successfully earned their Doctor of Philosophy (PhD) degree in Biochemistry and Molecular Biology.

Location

Boston, United States

Links

Previous companies


Org chart

No direct reports

Teams


Offices


Vor Biopharma

3 followers

Vor Biopharma is an immuno-oncology company that develops therapies for treating cancer. It is focused on developing technologies that can enable selective targeting of cancer cells without impacting normal cells.


Industries

Employees

51-200

Links